An analysis of metastatic melanoma patients (GEO: GSE145996) found that activating mutations in the NF‐κB inhibitor NFKBIE were exclusively present in patients who responded to immunotherapy, suggesting that heightened NF‐κB signaling may prime a more effective anti‐tumor immune response in certain contexts [88]. This evidence concerns the gene NFKB1 and metastatic melanoma.